SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 1,598.82 |
Enterprise Value ($M) | 1,940.97 |
Book Value ($M) | -30.45 |
Book Value / Share | -0.35 |
Price / Book | -52.50 |
NCAV ($M) | -210.12 |
NCAV / Share | -2.41 |
Price / NCAV | -7.61 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.94 |
Return on Assets (ROA) | -0.45 |
Return on Equity (ROE) | -1.75 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.68 |
Current Ratio | 1.71 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 324.74 |
Assets | 504.41 |
Liabilities | 534.86 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Deep Track Capital, LP | 0.70 | -92.93 | |
13G | Woodline Partners LP | 5.70 | ||
13G/A | Armistice Capital, Llc | 10.00 | 3.58 | |
13G/A | Vanguard Group Inc | 9.02 | 0.00 | |
13G/A | Morgan Stanley | 1.70 | -68.22 | |
13G/A | State Street Corp | 3.60 | -48.87 | |
13G | Rock Springs Capital Management LP | 5.79 | ||
13G/A | Macquarie Group Ltd | 6.31 | 33.47 | |
13G/A | Janus Henderson Group Plc | 0.00 | -99.37 | |
13G/A | Adage Capital Partners Gp, L.l.c. | 0.67 | -88.69 | |
13G/A | BlackRock, Inc. | 10.60 | 3.74 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
807,946 | 1,683,336 | 48.00 | |
228,921 | 574,488 | 39.85 | |
216,924 | 624,370 | 34.74 | |
(click for more detail) |
Similar Companies | |
---|---|
TRDA – Entrada Therapeutics, Inc. | TRVI – Trevi Therapeutics, Inc. |
TSBX – Turnstone Biologics Corp. | URGN – UroGen Pharma Ltd. |
VCEL – Vericel Corporation |
Financial data and stock pages provided by
Fintel.io